Perrigo (PRGO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
02-28

For the quarter ended December 2024, Perrigo (PRGO) reported revenue of $1.14 billion, down 1.6% over the same period last year. EPS came in at $0.93, compared to $0.86 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.2 billion, representing a surprise of -4.77%. The company delivered an EPS surprise of +1.09%, with the consensus EPS estimate being $0.92.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Perrigo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Sales- Consumer Self-Care Americas (CSCA): $744.10 million compared to the $766.89 million average estimate based on three analysts. The reported number represents a change of 0% year over year.
  • Net Sales- Consumer Self-Care International (CSCI): $394.10 million versus the three-analyst average estimate of $422.82 million. The reported number represents a year-over-year change of -4.5%.
  • Net Sales- CSCA- Oral care: $70.60 million versus $72.34 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.4% change.
  • Net Sales- CSCA- Nutrition: $145.70 million versus the two-analyst average estimate of $147.32 million. The reported number represents a year-over-year change of +14%.
  • Net Sales- CSCA- Healthy Lifestyle: $85.50 million versus $92.30 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -6.7% change.
  • Net Sales- CSCA- Upper Respiratory: $130.30 million compared to the $133.24 million average estimate based on two analysts. The reported number represents a change of -4.9% year over year.
  • Gross Profit- Consumer Self-Care International- Adjusted (CSCI): $194.40 million compared to the $220.42 million average estimate based on three analysts.
  • Gross Profit- Consumer Self-Care Americas- Adjusted (CSCA): $229.10 million versus $256.58 million estimated by three analysts on average.
View all Key Company Metrics for Perrigo here>>>

Shares of Perrigo have returned +0.9% over the past month versus the Zacks S&P 500 composite's -2.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Perrigo Company plc (PRGO) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10